Apremilast Efficacy Results Disappoint But May Be Enough For Commercial Success
This article was originally published in Pharmaceutical Approvals Monthly
Celgene’s PDE-4 inhibitor met the primary endpoint in the first of two pivotal psoriasis trials, but analysts worried that the treatment effect was less than that seen in a Phase II study. Some analysts see a niche for apremilast in treatment-naïve patients before they move on to biologic therapy. Celgene aims to begin apremilast regulatory filings this autumn, first targeting psoriatic arthritis.